ADVA
13.5.2020 09:02:19 CEST | Business Wire | Press release
ADVA (FSE: ADV) and 6WIND today announced that German telecommunication carrier WiTCOM is using ADVA’s Ensemble Connector and 6WIND’s Turbo IPsec vRouter as key components of its new edge cloud platform. The open multi-vendor solution enables WiTCOM to power its smart city initiative with network functions virtualization (NFV) and universal customer premises equipment (uCPE). Built on best-of-breed technology from five leading suppliers, the solution supports the rapid and efficient rollout of IoT, video and next-generation services across WiTCOM’s IPv6 network and enables easy scalability for global deployments. Other partners in the project are Advantech, dacoso and Dell Technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005054/en/
“We took an innovative approach for an open multi-vendor solution to power our smart city initiative working with 6WIND, ADVA, Advantech, Dell Technologies and dacoso,” said Volker Bodenbach, head of technology and operations, WiTCOM. “Together we designed a secure open platform that powers edge cloud for IoT, video and next-generation services across our IPv6 network that can further be deployed worldwide across many verticals.”
WiTCOM’s new multi-vendor platform is composed of technologies optimized for edge cloud architecture. The uCPE approach brings dramatically increased efficiency and scale to the ICT service provider’s business. It also ensures that its customers benefit from ultimate choice and flexibility. Now, WiTCOM can streamline multiple virtual network functions (VNFs) on a single installation deployed close to the end customer, helping cities to digitalize their infrastructure and take advantage of the latest innovation in areas such as traffic control, surveillance and IoT.
“Our Ensemble Connector is the ideal solution for hosting and managing demanding uCPE applications. It’s now giving WiTCOM the power of the cloud along with several other benefits, such as zero-touch provisioning and platform security. It also provides access to the Ensemble Harmony ecosystem, which includes a wide variety of onboarded commercial VNFs,” commented James Buchanan, general manager, Edge Cloud, ADVA. “With its new uCPE network, WiTCOM can respond in an instant to customer demands and empower municipal networks to test out offerings and ideas. It will help accelerate the fourth industrial revolution and be a key tool in transforming cities into safer, less wasteful and more pleasant places to live.”
“6WIND’s vRouters provide the high-performance virtual routing foundation required for secure, scalable uCPE solutions,” said Eric Carmès, founder and CEO, 6WIND. “We are proud to work with WiTCOM alongside our partners ADVA, Advantech, dacoso and Dell Technologies to create an industry-leading smart city initiative for IoT, video and additional services.”
“Our task was to combine the components for this managed edge cloud solution into a finely tuned overall solution,” explained Karsten Geise, head of business and development, dacoso. “IoT via IPv6 public networks will be of great interest to many companies in the future if it meets such high security and automation requirements.”
“WiTCOM’s smart city blueprint extends the cloud infrastructure to the IoT edge, building a solid and open foundation to run innovative mobility and security services,” said James Yang, VP, Cloud-IoT Group, Advantech. “Our white box uCPE solutions help service providers like WiTCOM enable this intelligent edge with optimized platforms that provide ample computing power and rich connectivity while meeting edge environmental and mechanical constraints.”
Further information is available in this case study: https://adva.li/witcom-case-study .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at: www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005054/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom